A team of scientists from Cleveland Clinic’s Lerner Research Institute, Johns Hopkins University School of Medicine and Johns Hopkins Drug Discovery has synthesized and tested a new class of gut-restricted oral therapies that shows promise in treating inflammatory bowel disease.
Read MoreIdentifying Actionable Cancer Mutations
Researchers have developed a personalized genomic medicine platform to identify clinically actionable mutations and accelerate the development of cancer precision medicine protocols.
Study Reveals Cause of Common Zika Virus Birth Defect
Defining the molecular mechanisms that drive the abnormal brain development associated with Zika virus infection.
New Frontiers in Epithelial Barrier Research
Researchers have clarified the essential protective role of Β-actin in regulating the epithelial barrier and intestinal inflammation.
Novel Model Helps Researchers Identify Actionable Drug Target for Ulcerative Colitis
Researchers engineer novel disease model to develop new drugs for the treatment of ulcerative colitis. Physician-researcher Emina Huang, MD, explains what makes this model unique.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Genetic Factors May Influence COVID-19 Susceptibility
A new study has identified genetic factors that may influence susceptibility to COVID-19, which could guide personalized treatment. Feixiong Cheng, PhD, explains the implications of his findings.
Germline Genomic Profiles of Children, Adolescents and Young Adult with Solid Tumors Inform Management and Treatment
Researchers demonstrate the value of genetics evaluation and genetic testing in children, adolescents and young adults with solid tumors. Charis Eng, MD, PhD, gives insight into the largest-to-date evaluation of germline mutations in this population.
Network-Based Drug Discovery for the Emerging COVID-19 Epidemic
Traditional methods of drug discovery cannot keep up with the rapid emergence and mutation of human coronavirus epidemics. Feixiong Cheng, PhD, has applied a network-based prediction model to identify targets for drug repurposing for the treatment of COVID-19.
Harnessing Artificial Intelligence for Drug Repurposing
One driver of increased pharmaceutical spending is the high failure rate of expensive and time-consuming randomized control trials. deepDTnet, a network-based deep learning methodology for novel target identification and in silico drug repurposing, may aid in the development of novel, effective treatment strategies for complex diseases.
Common Measures of Immune Status, Inflammation Can Predict Mortality
The association between low lymphocyte levels and reduced survival is strengthened when present in combination with other blood abnormalities. Epidemiologist Jarrod Dalton, PhD, discusses his findings, which suggest that lymphocyte count, red blood cell distribution width and C-reactive protein levels can be used as pragmatic immune status indicators in routine preventive care.
Network-Based Tool Predicts Disease Comorbidities
Patterns of miRNA-regulated gene expression may provide insight into disease-disease relationships. Researchers have developed a new analytic tool to predict disease comorbidities based on these miRNA-mediated pathways, which may aid in the development of personalized treatments.